XOMA Corporation (XOMA) Shares are Up 21.32%

XOMA Corporation (XOMA) : Traders are bullish on XOMA Corporation (XOMA) as it has outperformed the S&P 500 by a wide margin of 13% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 21.4%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 21.32% in the last 1 week, and is up 16.8% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

The stock has recorded a 20-day Moving Average of 22.78% and the 50-Day Moving Average is 12.36%. XOMA Corporation has dropped 18.17% during the last 3-month period . Year-to-Date the stock performance stands at -49.55%.


XOMA Corporation (NASDAQ:XOMA): stock turned positive on Friday. Though the stock opened at $0.58, the bulls momentum made the stock top out at $0.69 level for the day. The stock recorded a low of $0.58 and closed the trading day at $0.671, in the green by 15.65%. The total traded volume for the day was 2,278,777. The stock had closed at $0.5802 in the previous days trading.

XOMA Corporation is engaged in the discovery and development of antibody-based therapeutics. The Companys lead product candidate, gevokizumab, is a potent, humanized allosteric-modulating monoclonal antibody that binds to the inflammatory cytokine interleukin-1 beta (IL-1 beta). The Company has initiated three pivotal clinical trials evaluating gevokizumab for the treatment of non-infectious intermediate, posterior or pan-uveitis (NIU) and Behcets disease uveitis. The Company also has a gevokizumab Proof-of-Concept (POC) development program to identify other illness for late-stage development. These studies are known as the EYEGUARD program, which includes EYEGUARD-A (patients with active NIU), EYEGUARD-B (patients with Behcets disease uveitis outside of the United States), and EYEGUARD-C (patients with a history of NIU controlled with systemic treatment).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.